Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of CancerDecision ResourcesDecember 14, 2005 14 Pages - SKU: DECR1195333 |
| Bisphosphonates have been in use for approximately 25 years, most commonly to treat diseases characterized by bone loss, such as osteoporosis. Bisphosphonates are also used in adjunctive treatment of cancers that involve bone-related complications. Currently, bisphosphonates are approved only for the treatment of patients with advanced cancer who have bone metastases, but researchers are investigating the direct antitumor effects of these agents and their benefits in treating bone loss resulting from hormonal cancer treatment. In this report, we present an overview of bisphosphonate treatment, including a description of bone remodeling, currently available agents, and safety concerns. We discuss the use of bisphosphonates in the treatment of bone metastases and bone loss in breast and prostate cancer patients and as antitumor agents. We also profile emerging nonbisphosphonate agents that target bone and may pose significant competition for bisphosphonates.
Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
- Diseases & Conditions
- Osteoporosis
- Pharmaceuticals
- Manufacturing, Packaging & Detailing
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
